ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
World Health Organization, 2010. Progress Report 2000–2009 and Strategic Plan 2010–2020 of the Global Programme to Eliminate Lymphatic Filariasis: Halfway Towards Eliminating Lymphatic Filariasis. Geneva: World Health Organization, WHO/HTM/NTD/PCT/2010.6.
-
2.
Ottesen EA, 2006. Lymphatic filariasis: treatment, control, and elimination. Adv Parasitol 61: 395–441.
-
3.
Ramzy RM, El Setouhy M, Helmy H, Ahmed ES, Abd Elaziz KM, Farid HA, Shannon WD, Weil GJ, 2006. Effect of yearly mass drug administration with diethycarbamazine and albendazole on bancroftian filariasis in Egypt: a comprehensive assessment. Lancet 367: 992–999.
-
4.
World Health Organization, 2003. Global Progam to Eliminate Lymphatic Filariasis. Annual Report on Lymphatic Filariasis 2003. Geneva: World Health Organization.
-
5.
Ramzy RM, Goldman AS, Kamal HA, 2005. Defining the cost of the Egyptian lymphatic filariasis elimination programme. Filaria J 4: 7.
-
6.
Mathieu E, Lammie PJ, Radday J, Beach MJ, Streit T, Wendt J, Addiss DG, 2004. Factors associated with participation in a campaign of mass treatment against lymphatic filariasis, in Leogane, Haiti. Ann Trop Med Parasitol 98: 703–714.
-
7.
Babu BV, Hazra RK, Chhotray GP, Satyanarayana K, 2004. Knowledge and beliefs about elephantiasis and hydrocele of lymphatic filariasis and some socio-demographic determinants in an endemic community of eastern India. Public Health 118: 121–127.
-
8.
Mathieu E, Direny AN, de Rochars MB, Streit TG, Addiss DG, Lammie PJ, 2006. Participation in three consecutive mass drug administrations in Leogane, Haiti. Trop Med Int Health 11: 862–868.
-
9.
Ramaiah KD, Das PK, Vanamail P, Pani SP, 2003. The impact of six rounds of single-dose mass adminstration of diethylcarbamazine or ivermectin on the transmission of Wuchereria bancrofti by Culex quinquefasciatus and its implications for lymphatic filariasis elimination programmes. Trop Med Int Health 8: 1082–1092.
-
10.
Fraser M, Taleo G, Taleo F, Yaviong J, Amos M, Babu M, Kalkoa M, 2005. Evaluation of the program to eliminate lymphatic filariasis in Vanuatu following two years of mass drug administration implementation: results and methodologic approach. Am J Trop Med Hyg 73: 753–758.
-
11.
TDR, 2000. Community-Directed Treatment of Lymphatic Filariasis in Africa. Report of a Multicenter Study in Ghana and Kenya. Geneva: World Health Organization.
-
12.
Cantey PT, Rout J, Rao G, Williamson J, Fox LM, 2010. 2010: increasing compliance with mass drug administration programs for lymphatic filariasis in India through education and lymphedema management programs. PLoS Negl Trop Dis 4: e728.
-
13.
Babu BV, Kar SK, 2004. Coverage, compliance and some operational issues of mass drug administration during the programme to eliminate lymphatic filariasis in Orissa, India. Trop Med Int Health 9: 701–709.
-
14.
World Health Organization, 2011. Monitoring and Epidemiological Assessment of Mass Drug Administration in the Global Programme to Eliminate Lymphatic Filariasis: A Manual for National Elimination Programmes. Geneva: World Health Orgnaization, WHO/HTM/NTD/PCT/2011.4.
-
15.
World Bank, 2008. Arab Republic of Egypt National Schistomiasis Control Project. Available at: http://siteresources.worldbank.org/EXTWBASSHEANUTPOP/Resources/egypt_schistosomiasis_ppar.pdf. Accessed February 2013.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 457 | 428 | 35 |
| Full Text Views | 384 | 12 | 1 |
| PDF Downloads | 120 | 8 | 1 |
Knowledge and Practice Related to Compliance with Mass Drug Administration during the Egyptian National Filariasis Elimination Program
Khaled M. Abd Elaziz
Khaled M. Abd Elaziz
Department of Community, Environmental, and Occupational Medicine, Faculty of Medicine, and Research and Training Center on Vector of Diseases Ain Shams University, Cairo, Egypt; Global Community Partnerships, GlaxoSmithKline, Brentford, United Kingdom; Infectious Diseases Division, Department of Internal Medicine, Washington University School of Medicine, Saint Louis, Missouri
Search for other papers by Khaled M. Abd Elaziz in
Current site
Google Scholar
PubMed
Search for other papers by Khaled M. Abd Elaziz in
Current site
Google Scholar
PubMed
Maged El-Setouhy
Maged El-Setouhy
Department of Community, Environmental, and Occupational Medicine, Faculty of Medicine, and Research and Training Center on Vector of Diseases Ain Shams University, Cairo, Egypt; Global Community Partnerships, GlaxoSmithKline, Brentford, United Kingdom; Infectious Diseases Division, Department of Internal Medicine, Washington University School of Medicine, Saint Louis, Missouri
Search for other papers by Maged El-Setouhy in
Current site
Google Scholar
PubMed
Search for other papers by Maged El-Setouhy in
Current site
Google Scholar
PubMed
Mark H. Bradley
Mark H. Bradley
Department of Community, Environmental, and Occupational Medicine, Faculty of Medicine, and Research and Training Center on Vector of Diseases Ain Shams University, Cairo, Egypt; Global Community Partnerships, GlaxoSmithKline, Brentford, United Kingdom; Infectious Diseases Division, Department of Internal Medicine, Washington University School of Medicine, Saint Louis, Missouri
Search for other papers by Mark H. Bradley in
Current site
Google Scholar
PubMed
Search for other papers by Mark H. Bradley in
Current site
Google Scholar
PubMed
Reda M. R. Ramzy
Reda M. R. Ramzy
Department of Community, Environmental, and Occupational Medicine, Faculty of Medicine, and Research and Training Center on Vector of Diseases Ain Shams University, Cairo, Egypt; Global Community Partnerships, GlaxoSmithKline, Brentford, United Kingdom; Infectious Diseases Division, Department of Internal Medicine, Washington University School of Medicine, Saint Louis, Missouri
Search for other papers by Reda M. R. Ramzy in
Current site
Google Scholar
PubMed
Search for other papers by Reda M. R. Ramzy in
Current site
Google Scholar
PubMed
Gary J. Weil
Gary J. Weil
Department of Community, Environmental, and Occupational Medicine, Faculty of Medicine, and Research and Training Center on Vector of Diseases Ain Shams University, Cairo, Egypt; Global Community Partnerships, GlaxoSmithKline, Brentford, United Kingdom; Infectious Diseases Division, Department of Internal Medicine, Washington University School of Medicine, Saint Louis, Missouri
Search for other papers by Gary J. Weil in
Current site
Google Scholar
PubMed
Search for other papers by Gary J. Weil in
Current site
Google Scholar
PubMed
Lymphatic filariasis (LF) has been targeted for global elimination by 2020. The primary tool for the program is mass drug administration (MDA) with antifilarial medications to reduce the source of microfilariae required for mosquito transmission of the parasite. This strategy requires high MDA compliance rates. Egypt initiated a national filariasis elimination program in 2000 that targeted approximately 2.7 million persons in 181 disease-endemic localities. This study assessed factors associated with MDA compliance in year three of the Egyptian LF elimination program. 2,859 subjects were interviewed in six villages. The surveyed compliance rate for MDA in these villages was 85.3% (95% confidence interval = 83.9–86.5%). Compliance with MDA was positively associated with LF knowledge scores, male sex, and older age. Adverse events reported by 18.4% of participants were mild and more common in females. This study has provided new information on factors associated with MDA compliance during Egypt's successful LF elimination program.
Author Notes
Financial support: This study was partially supported by National Institutes of Health grants AI-35855 and AI-65715 and by a grant from GlaxoSmithKline.
Authors' addresses: Khaled M. Abd Elaziz and Maged El-Setouhy, Faculty of Medicine, Department of Community, Environmental, and Occupational Medicine, Ain Shams University, Cairo, Egypt, E-mails: khaledabdu@yahoo.com and maged.elsetouhy@gmail.com. Mark H. Bradley, Global Community Partnerships, GlaxoSmithKline, Brentford, UK, E-mail: mark.h.bradley@gsk.com. Reda M. R. Ramzy, Egyptian Ministry of Health, National Nutrition Institute, Cairo, Egypt, E-mail: reda.mr.ramzy@gmail.com. Gary J. Weil, Infectious Diseases Division, Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO, E-mail: gweil@dom.wustl.edu.
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
World Health Organization, 2010. Progress Report 2000–2009 and Strategic Plan 2010–2020 of the Global Programme to Eliminate Lymphatic Filariasis: Halfway Towards Eliminating Lymphatic Filariasis. Geneva: World Health Organization, WHO/HTM/NTD/PCT/2010.6.
-
2.
Ottesen EA, 2006. Lymphatic filariasis: treatment, control, and elimination. Adv Parasitol 61: 395–441.
-
3.
Ramzy RM, El Setouhy M, Helmy H, Ahmed ES, Abd Elaziz KM, Farid HA, Shannon WD, Weil GJ, 2006. Effect of yearly mass drug administration with diethycarbamazine and albendazole on bancroftian filariasis in Egypt: a comprehensive assessment. Lancet 367: 992–999.
-
4.
World Health Organization, 2003. Global Progam to Eliminate Lymphatic Filariasis. Annual Report on Lymphatic Filariasis 2003. Geneva: World Health Organization.
-
5.
Ramzy RM, Goldman AS, Kamal HA, 2005. Defining the cost of the Egyptian lymphatic filariasis elimination programme. Filaria J 4: 7.
-
6.
Mathieu E, Lammie PJ, Radday J, Beach MJ, Streit T, Wendt J, Addiss DG, 2004. Factors associated with participation in a campaign of mass treatment against lymphatic filariasis, in Leogane, Haiti. Ann Trop Med Parasitol 98: 703–714.
-
7.
Babu BV, Hazra RK, Chhotray GP, Satyanarayana K, 2004. Knowledge and beliefs about elephantiasis and hydrocele of lymphatic filariasis and some socio-demographic determinants in an endemic community of eastern India. Public Health 118: 121–127.
-
8.
Mathieu E, Direny AN, de Rochars MB, Streit TG, Addiss DG, Lammie PJ, 2006. Participation in three consecutive mass drug administrations in Leogane, Haiti. Trop Med Int Health 11: 862–868.
-
9.
Ramaiah KD, Das PK, Vanamail P, Pani SP, 2003. The impact of six rounds of single-dose mass adminstration of diethylcarbamazine or ivermectin on the transmission of Wuchereria bancrofti by Culex quinquefasciatus and its implications for lymphatic filariasis elimination programmes. Trop Med Int Health 8: 1082–1092.
-
10.
Fraser M, Taleo G, Taleo F, Yaviong J, Amos M, Babu M, Kalkoa M, 2005. Evaluation of the program to eliminate lymphatic filariasis in Vanuatu following two years of mass drug administration implementation: results and methodologic approach. Am J Trop Med Hyg 73: 753–758.
-
11.
TDR, 2000. Community-Directed Treatment of Lymphatic Filariasis in Africa. Report of a Multicenter Study in Ghana and Kenya. Geneva: World Health Organization.
-
12.
Cantey PT, Rout J, Rao G, Williamson J, Fox LM, 2010. 2010: increasing compliance with mass drug administration programs for lymphatic filariasis in India through education and lymphedema management programs. PLoS Negl Trop Dis 4: e728.
-
13.
Babu BV, Kar SK, 2004. Coverage, compliance and some operational issues of mass drug administration during the programme to eliminate lymphatic filariasis in Orissa, India. Trop Med Int Health 9: 701–709.
-
14.
World Health Organization, 2011. Monitoring and Epidemiological Assessment of Mass Drug Administration in the Global Programme to Eliminate Lymphatic Filariasis: A Manual for National Elimination Programmes. Geneva: World Health Orgnaization, WHO/HTM/NTD/PCT/2011.4.
-
15.
World Bank, 2008. Arab Republic of Egypt National Schistomiasis Control Project. Available at: http://siteresources.worldbank.org/EXTWBASSHEANUTPOP/Resources/egypt_schistosomiasis_ppar.pdf. Accessed February 2013.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 457 | 428 | 35 |
| Full Text Views | 384 | 12 | 1 |
| PDF Downloads | 120 | 8 | 1 |